D.B. Root & Company LLC acquired a new position in shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,564 shares of the company’s stock, valued at approximately $458,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Frazier Financial Advisors LLC purchased a new stake in Merck KGaA during the 2nd quarter worth about $25,000. Rakuten Securities Inc. purchased a new position in shares of Merck KGaA in the 2nd quarter valued at about $27,000. Solstein Capital LLC acquired a new position in shares of Merck KGaA during the second quarter worth about $33,000. Burk Holdings LLC acquired a new position in shares of Merck KGaA during the second quarter worth about $39,000. Finally, Bard Associates Inc. purchased a new stake in shares of Merck KGaA during the second quarter worth approximately $60,000. 0.10% of the stock is currently owned by hedge funds and other institutional investors.
Merck KGaA Price Performance
Shares of Merck KGaA stock opened at $163.21 on Monday. Merck KGaA has a 52-week low of $116.68 and a 52-week high of $175.56. The company has a 50 day moving average of $162.62 and a 200 day moving average of $148.44. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $21.09 billion, a P/E ratio of 24.92 and a beta of 0.96.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Further Reading
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
